Evidence map›Paper›PMID 33641058›Full record

Trial reportInternational journal of hematology2021

Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study.

Hisashi Ishida, Mio Yano, Daiichiro Hasegawa, Tsukasa Hori, Yoshiko Hashii, Koji Kato, Takao Deguchi, Akiko Saito, Atsushi Sato, Hiroki Hori and 2 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 1 country.

Hisashi IshidaDepartment of Pediatrics, Okayama University Hospital, Okayama, Japan.
Mio YanoDepartment of Pediatrics, Kyoto City Hospital, Kyoto, Japan.
Daiichiro HasegawaDepartment of Hematology/Oncology, Kobe Children's Hospital, Kobe, Japan.
Tsukasa HoriDepartment of Pediatrics, Sapporo Medical University, Sapporo, Japan.
Yoshiko HashiiDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Koji KatoDepartment of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Takao DeguchiChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Akiko SaitoClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Atsushi SatoDepartment of Hematology/Oncology, Miyagi Children's Hospital, Sendai, Japan.
Hiroki HoriDepartment of Pediatrics, Mie University, Tsu, Japan.
Keizo HoribeClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Toshihiko ImamuraDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajiichou, Hirokouji Kawaramachidori, Kamigyo-ku, Kyoto, 602-8566, Japan. imamura@koto.kpu-m.ac.jp.ORCID http://orcid.org/0000-0002-5727-4470
National Hospital Organization · JPKobe Children's Hospital · JPKyoto City Hospital · JPKyoto Prefectural University of Medicine · JPMie University · JPMiyagi Children's Hospital · JPNational Center For Child Health and Development · JPOkayama University Hospital · JPSapporo Medical University · JPThe University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 90% of pediatric acute lymphoblastic leukemia (ALL) cases are curable with intensified chemotherapy, but very high-risk patients may require hematopoietic stem cell transplantation (HSCT). A suitable indication for HSCT in the first complete remission (CR1) should be defined to protect patients from long-term complications. We report the outcomes of HSCT in CR1 from the Japan Association of Childhood Leukemia Study (JACLS) ALL-02 study and reassess indications for HSCT. Of 1114 patients, 71 (6.4%) received HSCT in CR1. Indications included high-risk cytogenetic abnormalities and non-CR on day 33. Patients with B-cell precursor (BCP) ALL and a prednisolone poor response (PPR) received HSCT when leukocyte antigen-matched siblings were available. The 4-year overall survival (OS) of transplanted patients was 78.8% (confidence interval 67.3-86.6). Multivariate analysis revealed that cord blood transplantation was associated with poor OS. For BCP-ALL patients with PPR who achieved CR1 after induction therapy, HSCT in CR1 showed excellent outcomes (4-year OS 90.9%) but demonstrated no survival advantage as the outcome with chemotherapy was also excellent (4-year OS 97.0%). This study suggests that in BCP-ALL patients PPR is not an indication for HSCT in CR1. Precise evaluation of treatment responses would increase sophistication of indications for HSCT in CR1.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAllograftsChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantMalePrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrednisoloneRemission InductionSurvival RatePrednisoloneAcute lymphoblastic leukemiaChildrenHematopoietic stem cell transplantation

Identifiers

PMID33641058
OpenAlexW3135590782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.